Form 4 for EYPT EyePoint, Inc.
Accepted 2024-07-16 00:00:00 ET · period of report 2024-07-12 · accession 0001562180-24-005752 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2024-07-16 | 2024-07-12 | EYPT | GUYER DAVID R | Dir | S - Sale+OE | $10.06 | -11.6K | 1,850 | -86% | -$116.9K |
| DMT | 2024-07-16 | 2024-07-12 | EYPT | GUYER DAVID R | Dir | M - OptEx | $3.34 | +9,775 | 13.5K | +264% | +$32.6K |
| DMT | 2024-07-16 | 2024-07-12 | EYPT | GUYER DAVID R | Dir | M - OptEx | $0.00 | -9,775 | 3,250 | -75% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-07-12 | S | D | 11,625 | $10.06 | 1,850 | D | — | — | (F1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.00 to $10.125. The reporting person undertakes to provide EyePoint Pharmaceuticals Inc., any security holder of EyePoint Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| 2 | Common | Common Stock | 2024-07-12 | M | A | 3,250 | $3.50 | 6,950 | D | — | — | |
| 3 | Common | Common Stock | 2024-07-12 | M | A | 6,525 | $3.26 | 13,475 | D | — | — | |
| 4 | Derivative | Stock Option (Right to Buy) | 2024-07-12 | M | D | 6,525 | $0.00 | 6,525 | D | $3.26 · 2024-01-06 to 2033-06-19 | 6,525 Common Stock | |
| 5 | Derivative | Stock Option (Right to Buy) | 2024-07-12 | M | D | 3,250 | $0.00 | 3,250 | D | $3.50 · 2024-02-23 to 2033-06-19 | 3,250 Common Stock |